Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) and Alnylam Pharma (ALNY)
at www.tipranks.com (Thu, 30-Apr 3:40 PM)
Evommune Secures $125 Million Private Placement Backed by Leading Healthcare Funds
Market Chameleon (Fri, 13-Feb 11:54 AM)
EVMN’s EVO301 Delivers 33% Greater EASI Improvement in Atopic Dermatitis—Clinical Results Set Stage for Next Trial Phase
Market Chameleon (Tue, 10-Feb 10:28 AM)
EVO301 Delivers 33% Placebo-Adjusted Efficacy in Moderate-to-Severe Atopic Dermatitis—No Serious Side Effects Reported, Phase 2a Results Show
Market Chameleon (Tue, 10-Feb 8:22 AM)
